AMBUJACEM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | AMBUJACEM | Market Cap | 1,05,369 Cr. | Current Price | 424 ₹ | High / Low | 625 ₹ |
| Stock P/E | 27.0 | Book Value | 213 ₹ | Dividend Yield | 0.47 % | ROCE | 3.29 % |
| ROE | 7.70 % | Face Value | 2.00 ₹ | DMA 50 | 438 ₹ | DMA 200 | 492 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | -0.02 % | PAT Qtr | 1,742 Cr. | PAT Prev Qtr | -59.2 Cr. |
| RSI | 46.2 | MACD | -4.31 | Volume | 22,64,633 | Avg Vol 1Wk | 29,03,250 |
| Low price | 394 ₹ | High price | 625 ₹ | PEG Ratio | 1.98 | Debt to equity | 0.02 |
| 52w Index | 13.0 % | Qtr Profit Var | 214 % | EPS | 14.4 ₹ | Industry PE | 29.9 |
📊 AMBUJACEM shows moderate fundamentals for long-term investment. With ROE (7.70%) and ROCE (3.29%), the company demonstrates weak capital efficiency compared to peers. The P/E ratio (27.0) is slightly below the industry average (29.9), suggesting fair valuation. The PEG ratio (1.98) indicates valuations are stretched relative to growth. Dividend yield (0.47%) provides minimal passive income. Debt-to-equity is very low (0.02), ensuring financial stability. Quarterly PAT surged to 1,742 Cr. from -59.2 Cr., reflecting strong recovery, though sustainability needs monitoring. EPS (14.4 ₹) is modest given the market cap.
💡 Entry Price Zone: A favorable entry would be between 400 ₹ – 430 ₹, closer to DMA 50 (438 ₹) and near the 52-week low (394 ₹), where valuations align better with long-term growth potential.
📈 Exit Strategy / Holding Period: If already holding, consider a 3–5 year horizon given fair valuations and recovery momentum. Partial profit booking may be considered near 500–550 ₹ if earnings growth sustains. Exit only if ROE/ROCE fail to improve or if PEG ratio remains high without EPS growth.
🌟 Positive
- [P/E ratio](ca://s?q=Explain_P/E_ratio) of 27.0 is slightly below industry average (29.9), suggesting fair valuation.
- Low [debt-to-equity](ca://s?q=Debt_to_equity_explained) ratio of 0.02 ensures financial stability.
- Quarterly PAT surged to 1,742 Cr., showing strong recovery.
- EPS of 14.4 ₹ provides earnings visibility.
- FII holdings increased slightly (+0.03%), showing foreign investor confidence.
⚠️ Limitation
- Weak [ROE](ca://s?q=Explain_ROE) (7.70%) and [ROCE](ca://s?q=Explain_ROCE) (3.29%) show poor capital efficiency.
- [PEG ratio](ca://s?q=PEG_ratio_explained) of 1.98 reflects stretched valuations relative to growth.
- Dividend yield of 0.47% offers minimal passive income.
- DII holdings decreased slightly (-0.02%), reflecting reduced domestic institutional interest.
- Stock trading at ~13% of 52-week index, reflecting weak price momentum.
📰 Company Negative News
- Weak capital efficiency metrics compared to peers.
- Muted institutional activity with DII reduction.
📢 Company Positive News
- Quarterly profit turnaround from -59.2 Cr. to 1,742 Cr.
- Low debt levels enhance financial resilience.
- Fair valuation compared to industry peers.
🏭 Industry
- Industry P/E at 29.9, slightly higher than company’s 27.0, showing sector-wide premium valuations.
- Cement sector growth driven by infrastructure expansion and housing demand, though margins remain cyclical.
✅ Conclusion
AMBUJACEM is a moderately strong candidate for long-term investment with fair valuations and strong profit recovery, but weak ROE and ROCE limit attractiveness. Entry is ideal near 400–430 ₹. Long-term investors may hold for 3–5 years, while existing holders can consider partial profit booking near 500–550 ₹ if momentum sustains. Monitoring capital efficiency and quarterly earnings will be crucial for sustained returns.